We are proud to announce that Oxford Immune Algorithmics (OIA), creator of Algocyte, is part of the Creative Destruction Lab-Toronto Health Diagnostics Stream’s 2020/21 graduating cohort, and was one of the top two performers in the CDL-- Atlanta Recovery Stream 2020/2021. The nine-month odyssey that started in Atlanta, U.S. and ended in Toronto, Canada, marks not only a significant milestone for OIA, but one that has positively altered the trajectory of the company.
The OIA team, led by its founders, interacted with leading academics and business leaders in medicine, business and science, who engaged and challenged us through intensive, multiple-to-one and one-on-one sessions. The CDL program works as a marketplace with four checkpoints where high calibre mentors, including former directors of national health institutions, venture capitalists and top academics, vote to save start-ups from elimination, helping them to make it through to the next session.
Around 400 worldwide start-ups, ready to help the world recover from the pandemic, applied to join the CDL Recovery stream in 2020. Twenty were selected and only two graduated, one of which was OIA. We are honoured to be acknowledged and chosen by such a distinguished group of world leaders.
With the help of CDL and its mentors, OIA has reached several new milestones, including establishing a biochemical lab in Atlanta, in partnership with Georgia Tech, to advance our microfluidics technology; fundraising and closing a £5.1M seed round led by Medtech AI; and welcoming Pam Winsor, former CMO of Medtronic Canada, who joined OIA's board as Chair.
The Creative Destruction Lab is a seed-stage accelerator that began in 2012 at the University of Toronto’s Rotman School of Management and currently runs ten accelerators in the U.S, Europe and Canada. In addition, it is an engine for scaling and funding deep tech companies, supporting CDL’s “innovative mindset,” and one of its key focus areas is computational health. The not-for-profit is funded by the Canadian government’s Strategic Innovation Fund and includes accelerators from future and space tech, artificial intelligence, blockchain, smart cities, health and quantum computing.
Oxford Immune Algorithmics (OIA) is an award-winning Deep MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.